Abstract 2145
Background
The pathological classification of pancreatic neuroendocrine neoplasms (PanNENs) has been revised based on the World Health Organization (WHO) 2017 classification. Well-differentiated PanNENs were previously classified as G1, G2, or G3 according to the Ki-67 labeling index (LI), which shows the cell proliferation ability. Although the Ki67 LI cut-off for G1 and G2 was changed from ≤2% to < 3% from WHO 2010 to 2017, there are few reports on the impact of G2 tumor malignancy associated with this change.
Methods
Patients with PanNENs G1/G2 classified by WHO 2017 Ki-67 LI cut-off who underwent pancreatic resection at our institution between July 1987 and March 2019 were retrospectively analyzed. We excluded patients with synchronous distant metastasis at the time of diagnosis. Their clinicopathological variables were analyzed.
Results
Sixty-two patients (median age: 58 years; range: 18–84 years) were examined. The G1/G2 groups comprised 40/22 and 48/14 patients based on WHO 2010 and 2017 classifications, respectively. Eight patients were reclassified from G2 to G1, two of which were T2 or more based on TNM classification; one patient had lymph node metastasis positivity, and all patients survived without recurrence. Disease recurrence occurred in 4/4 G1/G2 patients according to both WHO 2010 and 2017. G2 patients had shorter 5- and 10-year disease-free survivals (DFSs) than those of G1 patients based on WHO 2010 (90.9% and 90.9% vs. 84.5% and 70.4%, p = 0.179) and significantly shorter DFS based on WHO 2017 (91.9% and 91.9% vs. 78.6% and 58.9%, p = 0.036). The Ki-67 LI cut-off by ROC analysis was 3%, supporting the WHO 2017 classification. In multivariate analysis for DFS, tumor size >25 mm and vascular invasion positivity, but not G2, were risk factors for recurrence. The high-risk group with these factors had significantly worse 5- and 10-year disease-specific survivals (DSSs) compared to the low-risk group (100% and 100% vs. 90.9% and 68.2%, p = 0.045).
Conclusions
Revision of the Ki-67 LI cut-off for PanNENs G1/G2 based on WHO 2017 may be appropriate but G2 is not a risk factor for DFS. Tumor size >25 mm and vascular invasion positivity are potential risk factors. High-risk patients should be closely monitored during follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract